^
Association details:
| Biomarker: | Chr t(4;14) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Darzalex (daratumumab) (CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Published date:
09/24/2020
Excerpt:
High-risk MM was defined as the presence of t(4;14), t(14;16), or del(17p)….Of 5194 studies screened, 6 phase 3 trials were eligible, including 3 trials for newly diagnosed MM (2528 patients; 358 with HRMM) and 3 trials for relapsed or refractory MM (1533 patients; 222 with HRMM). Among patients with newly diagnosed HRMM, the addition of daratumumab to backbone regimens was associated with improved PFS (pooled HR, 0.67; 95% CI, 0.47-0.95; P = .02), with little evidence of heterogeneity (Cochran Q, P = .77; I2 = 0%).
DOI:
10.1001/jamaoncol.2020.4338
Source:
Title:
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Excerpt:
...- Presence of t(4;14) or del 17p, del 13q or 1q gain by conventional cytogenetics or fluorescence in situ hybridization (FISH) studies....
Trial ID:
